Bioalmanac
LL-37
Cathelicidin LL-37 · hCAP18 · CAMP peptide
The human body's own antimicrobial peptide, part of innate immunity. Genuinely important biology, and implicated in causing disease as often as treating it.
Storage
- Freeze-dried powder
- Refrigerated at 2–8 °C, protected from light.
- After mixing
- Refrigerated at 2–8 °C. Do not freeze once mixed. LL-37 adsorbs to plastic, so a substantial fraction can be lost to the walls of the container. Glass is preferable.
- Long-term, frozen
- Unopened powder is stable at −20 °C or colder.
Reconstitution — 5 mg vial, 200 mcg dose
On a 1 mL U-100 syringe. Check every figure against your own vial before drawing.
| Water added | Concentration | Volume to draw | Units | Doses per vial |
|---|---|---|---|---|
| 1 mL | 5 mg/mL | 0.04 mL | 4 units | 25 |
| 2 mL | 2.5 mg/mL | 0.08 mL | 8 units | 25 |
| 3 mL | 1.667 mg/mL | 0.12 mL | 12 units | 25 |
| 5 mL | 1 mg/mL | 0.2 mL | 20 units | 25 |
Dose ranges reported in sources
Descriptions of what sources report, not recommendations.
| Goal | Range | Frequency | Source |
|---|---|---|---|
| Topical application, as studied | 500–3200 mcg | Applied to the wound twice weekly in the trial protocol | Clinical trial |
| Commonly described community protocol, injected | 100–500 mcg | Daily, in short courses | Community practice |
When to stop
- Any flare of rosacea, psoriasis, eczema or another inflammatory skin condition.
- New or worsening joint pain, rash or fatigue. LL-37 is implicated in lupus pathology, and this is how that presents.
- An injection site that becomes hot, spreading or produces pus.
- Any allergic response: rash, hives, facial swelling or difficulty breathing. Seek urgent care.
- Dark urine or unusual fatigue, which could indicate red cell damage.
Use your browser’s print dialog and choose “Save as PDF”. This block is hidden when printed.